- EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer
Miaomiao Zhang et al, 2024, Translational Oncology CrossRef - PTEN‐knockout regulates metabolic rewiring and epigenetic reprogramming in prostate cancer and chemoprevention by triterpenoid ursolic acid
Lujing Wang et al, 2022, The FASEB Journal CrossRef - EphA2 Promotes the Development of Cervical Cancer through the CXCL11/PD-L1 Pathway
Xinyue Zhao et al, 2022, Journal of Oncology CrossRef - A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high‐grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study
Margaret E. Macy et al, 2017, Pediatric Blood & Cancer CrossRef - Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model
Ahmed F. Salem et al, 2020, Cancers CrossRef - EphA2 signaling within integrin adhesions regulates fibrillar adhesion elongation and fibronectin deposition
Alexandra C Finney et al, 2021, Matrix Biology CrossRef - Nanomedicine for the Treatment of Advanced Prostate Cancer
Sonia Vicente‐Ruiz et al, 2021, Advanced Therapeutics CrossRef - A Hoechst Reporter Enables Visualization of Drug Engagement In Vitro and In Vivo: Toward Safe and Effective Nanodrug Delivery
Takuya Miyazaki et al, 2022, ACS Nano CrossRef - EphA2 Expression Regulates Inflammation and Fibroproliferative Remodeling in Atherosclerosis
Alexandra C. Finney et al, 2017, Circulation CrossRef - Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer
Ashwin Sachdeva et al, 2022, British Journal of Cancer CrossRef - Tumor microenvironment complexity and therapeutic implications at a glance
Roghayyeh Baghban et al, 2020, Cell Communication and Signaling CrossRef - Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo
Amanda K. Pearce et al, 2016, Pharmaceutical Research CrossRef - Precision Nanomedicines for Prostate Cancer
Anna Cifuentes-Rius et al, 2018, Nanomedicine CrossRef - Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells
Deok-Soo Han et al, 2022, Scientific Reports CrossRef - Serum promotes vasculogenic mimicry through the EphA2/VE-cadherin/AKT pathway in PC-3 human prostate cancer cells
Changhwan Yeo et al, 2019, Life Sciences CrossRef - Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small‐molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids
Ezgi Oner et al, 2021, Journal of Nanobiotechnology CrossRef - Nanoparticles and phototherapy combination as therapeutic alternative in prostate cancer: A scoping review
Liah Aira Dias Ferreira et al, 2023, European Journal of Pharmacology CrossRef - Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation
Yun Xiang et al, 2019, Biomedicine & Pharmacotherapy CrossRef - EphA8 acts as an oncogene and contributes to poor prognosis in gastric cancer via regulation of ADAM10
Yingjing Wang et al, 2019, Journal of Cellular Physiology CrossRef - Differential expression of EphA5 protein in gastric carcinoma and its clinical significance
Wei Zhang et al, 2019, Oncology Letters CrossRef